# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce amyloid diseases
- describe Alzheimer's disease
- discuss protein misfolding and oligomerization
- highlight need for therapeutic agents

## BRIEF SUMMARY OF THE INVENTION

- introduce yeast model system
- describe Aβ42 oligomerization
- outline screening methods
- discuss therapeutic agents
- contemplate treatment methods

## DETAILED DESCRIPTION OF THE INVENTION

- introduce novel compositions and methods for screening agents that interfere with Aβ42 oligomerization
- describe methods of screening for therapeutic agents for diseases associated with protein aggregation
- outline yeast-based assays for identifying candidate compounds that decrease translational readthrough
- describe the use of yeast strains with mutations in genes affecting membrane efflux pumps and permeability
- outline kits and methods for using yeast strains to screen for compounds that inhibit protein aggregation
- describe the types of candidate compounds that can be screened, including genetic agents, proteins, and small organic compounds
- discuss the use of combinatorial libraries and structural identification to identify and optimize therapeutic agents

### Model of Aβ42 Oligomerization

- describe the use of a yeast-based model to study Aβ42 oligomerization and its effects on translation termination

### Example 2

- demonstrate the formation of SDS-stable oligomers of AβMRF and their detection by immunoblotting

### Example 3

- analyze point mutants of AβMRF to demonstrate the role of Aβ42 in oligomerization

### Example 4

- investigate the effects of guanidine and Hsp104 on AβMRF oligomerization

### Example 5

- demonstrate Hsp104 interaction with AβMRF

### A Suppressible Allele

- describe suppressible allele for drug screening

### Example 7

- describe yeast strains and media
- outline plasmid construction
- detail yeast growth assay
- describe immunoblotting and immunoprecipitation

